CTKB · Cytek Biosciences, Inc. · Webcasts, Transcripts & Audio
$5.89
+0.30 (+5.37%)
At close · Oct 26
Return incl. dividend (before tax)
Market Cap
$726.61M
Shares
129.98M
Volume · Oct 26
1.24M
Avg daily vol (3M)
1.13M
Cytek Biosciences, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Cytek Biosciences, Inc. (CTKB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-04
Cytek Biosciences, Inc. (CTKB) Q3 2026 Earnings Call
Scheduled
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-16
Cytek Biosciences, Inc. (CTKB) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript
Positive tone
Reorganization into business units
Gross margin and tariff refund
Recurring revenue (service and reagents)
Revenue
$48.14M
▲ 5.6% YoY Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Cytek Biosciences, Inc. (CTKB) Q1 2026 Earnings Call Transcript
Positive tone
Q1 revenue and growth
Geographic performance
Recurring revenue (reagents and service)
Revenue
$44.13M
▲ 6.5% YoY Gross margin
48.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Cytek Biosciences, Inc. (CTKB) Q4 2025 Earnings Call Transcript
Positive tone
Quarterly and annual revenue performance
2026 financial guidance and outlook
Geographic performance and end markets
Revenue
$62.14M*
▲ 8.1% YoY Gross margin
52.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Cytek Biosciences, Inc. (CTKB) Q3 2025 Earnings Call Transcript
Positive tone
Geographic revenue performance
Recurring revenue growth (service and reagents)
Capital deployment and M&A
Revenue
$52.29M
▲ 1.5% YoY Gross margin
52.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Cytek Biosciences, Inc. (CTKB) Q2 2025 Earnings Call Transcript
Balanced tone
Recurring revenue (reagents and service)
Revenue performance and geographic mix
Gross margin drivers and one-time items
Revenue
$45.60M
▼ 2.2% YoY Gross margin
52.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript
Cautious tone
Service and reagent recurring revenue
APAC and rest of world growth
Tariffs and macro environment
Revenue
$41.46M
▼ 7.6% YoY Gross margin
48.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-15
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Call Transcript
Positive tone
Adjusted EBITDA and profitability leverage
Cytek Cloud and bioinformatics
China demand and stimulus
Revenue
$57.48M*
▼ 1.3% YoY Gross margin
58.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript
Positive tone
Instrument placements
International growth (EMEA, APAC, China)
Bioinformatics / Cytek Cloud
Revenue
$51.50M
▲ 7.3% YoY Gross margin
56.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript
Balanced tone
Product launches (ESP and spectral panel tool)
U.S. market weakness and elongated sales cycles
Installed base and replacement opportunity
Revenue
$46.62M
▼ 6.2% YoY Gross margin
54.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript
Positive tone
Luminex/Amnis/Guava integration
Organic revenue growth and resumption
Wuxi manufacturing facility
Revenue
$44.86M
▲ 21% YoY Gross margin
51.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-01
Cytek Biosciences, Inc. (CTKB) Q4 2023 Earnings Call Transcript
Positive tone
Luminex/Amnis/Guava acquisition integration
Geographic footprint and regions
Revenue growth and 2023 results
Revenue
$58.23M*
Gross margin
56.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Cytek Biosciences, Inc. (CTKB) Q3 2023 Earnings Call Transcript
Revenue
$48.00M
▲ 18.6% YoY Gross margin
56.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Cytek Biosciences, Inc. (CTKB) Q2 2023 Earnings Call Transcript
Revenue
$49.69M
▲ 23.7% YoY Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Cytek Biosciences, Inc. (CTKB) Q1 2023 Earnings Call Transcript
Revenue
$37.09M
▲ 5.8% YoY Gross margin
56.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Cytek Biosciences, Inc. (CTKB) Q4 2022 Earnings Call Transcript
Revenue
−$112.74M*
Gross margin
-26.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Cytek Biosciences, Inc. (CTKB) Q3 2022 Earnings Call Transcript
Revenue
$40.48M
▲ 17.7% YoY Diluted EPS
$-0.01
Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
Cytek Biosciences, Inc. (CTKB) Q2 2022 Earnings Call Transcript
Revenue
$40.16M
▲ 32.1% YoY Diluted EPS
$0.00
Gross margin
61.2%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
Cytek Biosciences, Inc. (CTKB) Q1 2022 Earnings Call Transcript
Revenue
$35.06M
▲ 44.5% YoY Diluted EPS
$0.02
Gross margin
57.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Cytek Biosciences, Inc. (CTKB) Q4 2021 Earnings Call Transcript
Revenue
−$86.88M*
Gross margin
-27.2%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Cytek Biosciences, Inc. (CTKB) Q3 2021 Earnings Call Transcript
Revenue
$34.38M
▲ 37% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
61.9%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 webcasts
Key facts
CIK
1831915
CUSIP
23285D109
13F (30d)
19 filings
19 filers
Visit website
Investor relations